Company profile
Spruce Biosciences, Inc.
NASDAQ: SPRB · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
40DFH 44DQ 33GM —SS 44
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ revenue growth (YoY), disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$39.0M
Employees
22
as of 2026-09-17
Market cap
$149.1M
as of 2026-09-17
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$39.0M-$39.0M2025
Operating income-$36.5M-$36.5M2025
Total assets$53.0M$53.0M2025
Liabilities$10.5M$10.5M2025
Equity$42.5M$42.5M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Spruce Biosciences, Inc.’s revenue?
Spruce Biosciences, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Nkarta, Inc.47DMinerva Neurosciences, Inc.38DImmuneering Corporation43DTuHURA Biosciences, Inc.36DHelix BioPharma Corp.——Corbus Pharmaceuticals Holdings, Inc.45DNeighbors
San Mateo →Key facts
CEOJavier Szwarcberg
SectorHealthcare
IndustryBiotechnology
HeadquartersDaly City, CA
ExchangeNASDAQ: SPRB
Employees22
IPO date2020-10-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.